Owner Novartis AG

Inventors Sharma, Sushil Kumar; Versace, Richard William; Sambucetti, Lidia; Remiszewski, Stacy W; Perez, Lawrence B.; Green, Michael, A.; Bair, Kenneth Walter

Agent Davies Collison Cave

Pub. Number AU-B-2001282129

PCT Pub. Number WO02/22577

Priority 60292232 18.05.01 US; 60229943 01.09.00 US

Filing date 30 August 2001

Wipo publication date 26 March 2002

Acceptance publication date 25 August 2005

C07D 209/16 Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 471/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07D 403/12 Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 417/12 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07C 259/06 Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups

A61P 035/00 Antineoplastic agents

A61K 031/16 - Amides, e.g. hydroxamic acids

A61K 031/4045

C07D 295/02 Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

C07D 519/00 Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or